Expert-Driven Psychiatry Case: LAIs for Schizophrenia: Switch from Oral Treatment, Ep5

Christoph Correll, MD explains the benefit for a switch from oral to LAI antipsychotic treatment for patients with schizophrenia.

“Long acting injectable antipsychotics, or LAIs, have the potential to reduce non-adherence, relapse, rehospitalization, and even mortality, even among patients with first-episode schizophrenia and with comorbid substance use disorder.”

Also see a side-by-side review of the characteristics of select first and second generation LAIs.

- - - - -
Presented by The Journal of Clinical Psychiatry.

Christoph Correll, MD, is professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and a medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital.